"Somos una institución integrada por un equipo de personas, profesionales y especialistas comprometidos con la salud y el bienestar de nuestros pacientes y la comunidad. Trabajamos en forma permanente en la mejora continua de la gestión para brindar el servicio de calidad que queremos para nuestra comunidad. Brindamos una amplia variedad de servicios en distintas especialidades con una mirada integral de la salud, a través de una atención de calidad centrada en el bienestar del paciente y su familia."

During the past decade, Centro de Investigacion; Clinica - Clinica Viedma S.A. conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 6 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 6 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro de Investigacion; Clinica - Clinica Viedma S.A." #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Amgen" with 2 trials sponsored, "Nektar Therapeutics" with 2 trials sponsored, "Corvus Pharmaceuticals, Inc." with 1 trials sponsored and "Polyphor Ltd." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Investigacion; Clinica - Clinica Viedma S.A." #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator and "BeiGene, Ltd." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Centro de Investigacion; Clinica - Clinica Viedma S.A." are "Chemotherapy-induced Thrombocytopenia" (2 trials), "Non-Small Cell Lung Cancer" (2 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Covid-19" (1 trials) and "Early Breast Cancer" (1 trials). Many other conditions were trialed in "Centro de Investigacion; Clinica - Clinica Viedma S.A." in a lesser frequency.

Most popular intervention types in "Centro de Investigacion; Clinica - Clinica Viedma S.A." are "Drug" (10 trials), "Biological" (3 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (3 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (2 trials), "Cisplatin" (2 trials), "Paclitaxel" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Investigacion; Clinica - Clinica Viedma S.A." are 12 trials for "All" genders.

Currently, there are NaN active trials in "Centro de Investigacion; Clinica - Clinica Viedma S.A.". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Centro de Investigacion; Clinica - Clinica Viedma S.A., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Investigacion; Clinica - Clinica Viedma S.A., 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".